Published in Cancer Discov on May 13, 2015
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget (2015) 1.00
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene (2015) 1.00
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol (2016) 0.85
Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer (2016) 0.84
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget (2016) 0.83
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget (2016) 0.81
MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker. Cancer Discov (2015) 0.81
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn (2016) 0.80
HGF-MET in cancer progression and biomarker discovery. Cancer Sci (2017) 0.80
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Oncologist (2016) 0.79
OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol (2017) 0.78
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther (2016) 0.78
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2017) 0.78
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. Invest New Drugs (2016) 0.77
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget (2016) 0.77
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist (2016) 0.77
Has MET met its match? Ann Transl Med (2016) 0.76
Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas? Ann Transl Med (2016) 0.76
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clin Cancer Res (2016) 0.76
MET/HGF pathway activation as a paradigm of resistance to targeted therapies. Ann Transl Med (2017) 0.75
Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy. Int J Mol Sci (2017) 0.75
Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Neoplasia (2017) 0.75
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol (2016) 0.75
Effective implementation of novel MET pharmacodynamic assays in translational studies. Ann Transl Med (2017) 0.75
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget (2016) 0.75
Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Transl Lung Cancer Res (2016) 0.75
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75
Update in Lung Cancer 2015. Am J Respir Crit Care Med (2016) 0.75
Liquid Biopsy in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2016) 0.75
Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. Am J Hum Genet (2015) 0.75
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. Respir Med Case Rep (2017) 0.75
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med (2017) 0.75
The role of alternative splicing in cancer. Transcription (2016) 0.75
MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. Transl Lung Cancer Res (2015) 0.75
Special issue: "MET as actionable target in cancer therapy". Ann Transl Med (2017) 0.75
Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J Clin Oncol (2016) 0.75
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer (2016) 0.75
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biol Med (2016) 0.75
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol (2017) 0.75
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer (2017) 0.75
Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer (2017) 0.75
Molecular classifications of gastric cancers: Novel insights and possible future applications. World J Gastrointest Oncol (2017) 0.75
(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics. Eur J Nucl Med Mol Imaging (2017) 0.75
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol (2017) 0.75
Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. Neurol Genet (2017) 0.75
Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer (2017) 0.75
Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun (2017) 0.75
Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch (2017) 0.75
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol (2017) 0.75
Molecular Testing of Lung Cancers. J Pathol Transl Med (2017) 0.75
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Oncotarget (2017) 0.75
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res (2014) 1.19
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov (2015) 0.96
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov (2017) 0.90
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res (2016) 0.88
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Clin Cancer Res (2016) 0.82
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clin Cancer Res (2016) 0.80
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res (2016) 0.76
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Med (2015) 0.75
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer (2017) 0.75